We conducted a 10-year retrospective chart review of 1,000 immunoth erapy-treated pati ents to evaluate the effi cacy and safe ty of serial dilution quantitative intradermal testin g in the mana gement of allergic rhinitis. Three months after the initiation ofimmunotherapy, these pati ents had been assessed to ascertain wheth er or not they had expe rienced any ove rall improvement in their initial symptoms. Also included in this evaluation were determinations of each pati ent's use of medications as well as the inciden ce of adv erse reactions to treatment and recurrent sinus infections. Wefound that 860 patients had achieved complete relief of their symptoms and required no other treatment ; the remainin g 140 patients experience d a partial improvement and continued to use pharmacotherapy to control breakthrough symptoms . During skin testing, only one patient expe rienced a systemic reaction, which responded to subcutane ous ep inephr ine. There were no death s. We conclude that serial dilut ion quantitative intradermal testing is saf e and that quantificat ion ofskin reactiv ity in evaluating and treatin g allergi c rhin itis with immunotherapy is completely effective in the vast majority of patients.
Introduction
Alle rgic rhin itis is the fifth mo st common chronic condition in the United States, affecting an estimated 36 million American s.1.2 Therefore, ensuring the efficacy and safety of skin testing in these patients is of extrem e importanc e.
Interventional mod alitie s for patients with allergic rhinitis include environmental control, immunotherapy, and treatment with pharmacol ogic agents such as deconges- tants , antih istamines, leukotriene inhibitors, and other mediator drugs. Sk in testing is the best-established and most sensitive indicator of allergic disea se. Several technique s are used to identify pertinent antigens in the treatment of inh alant allergies. The goal s of allergy testing and immunotherapy are to accurately identify and quanti fy each antigen to which the patient is allergic so that a therapeutic approach can be designed to provide symptom relief in a safe but exped ient manner.
Patients and methods
We reviewed the charts of I ,000 con secuti ve patients who had been treated with immunotherapy for allergic rhinitis between 1989 and 1999. These patients had been initially managed with environmental control, pharmacotherapy, and surgery when indi cated. When their symptoms persisted, they underwent further evaluation and treatment based on the results of serial dilution quantitative intraderm al skin testing. Three months after they had started immunotherapy, all patients were re-evaluated and their symptoms were reassessed . Also evalu ated were their use of med ications as well as the incidence of treatment-related adverse effects and recu rrent sinus infections that nece ssitated medical manag ement.
Results
During the initial 3 months of treatment, the se patients had undergone a total of 105,000 intradermal skin test s and had received a total of21 ,600 allergy injections. Only one patient experi enced a systemic reaction to testing (hive s and wheezing), which responded to one dose of subcutaneous epinephrine.
Of the 1,000 pat ients who were evalu ated, 860 had experienced a complete response to immunotherapy. The criteria for a complete response included the eradication of symptoms, the lack of a need for any allergy medication , and the abse nce of sinu s infection. The other 140 patients experienced a partial improvement, and they continued to take pharmacother apy to control breakthrough symptoms and infection.
Is your patie to tell you so
• ttylng ething?
Dry mouth due to radiation-induced xerostomia is not only uncomfortable, it can lead to oral health complications. 1 With the longest record of clinically proven efficacy and time proven safety of any prescription dry mouth treatment, Salagen Tablets can restore patients' natural protective saliva. Use of Salagen Tablets is supported by:
• More than 23,000,000 patient-days of therapy'
• Consiste nt, statistically significant improvements In addition, thefollowingadverse events(~3% incidence) werereported at dosages of 15-30 mglday inthecontrolledclinical trials: Headache(11%), dyspepsia (7%), lacrimation (6%), edema (5%), abdominal pai n (4%), amblyopia (4%), vomiting(4%), pharyngitis(3%), hypertension(3%).
The following events were reported withtreated head and neck cancer patients at incidences of 1% to 2% at dosages of 7.5 to 30 mglday: abnormal vision, conjunct ivitis, dysphagia. epistaxis, myalgias, pruritus, rash, sinusitis, tachycardia,taste perversion, tremor,voice alteration. In long-term treatment were two patients with underlying cardiovascular disease of whom one experienced a myocardial infarct and another an episode of syncope. The association withdrug is uncertain.
Sjogren's Syndrome Patients: In controlled studies, 376patients received pilocarpine, of whom 5% were men and 95% were women. Race distribution was 84% Caucasian, 9%Oriental, 3%Black, and 4%ofother origin. Mean age was 55 years.The majority of patients were between 40 and 69 years (70%), 16% were 70 years and olderand 14% were younger than40years ofage. Ofthese patients, 161 /629 (891376 receiving pilocarpine) wereover theageof65years.The adverse events reportedby those over 65 years and those 65 years and younger were comparable except fornotabletrends forurinary frequency, diarrhea, and dizziness. The incidences of urinary frequency and diarrhea in the elderly were about double those inthenon-elderly.The incidenceofdizziness was about three times ashigh in theelderly asin thenon-elderly.These adverse experiences were not considered to be serious. In the 2 placebo -controlled studies, themost common adverse events related to drug use were sweating, urinary frequency, chil ls, and vasodilatation (flush ing). The most commonly reported reason for patient discontinuation of treatment wassweating. Expected pharmacologic effects of pilocarpine include the following adverse experiences associatedwithSALAGEN ' Tablets: MANAGEMENT OF OVERDOSE: Fatal overdosage with pilocarpine has been reported in the scientific literatureat doses presumed to begreater than 100 mg in two hospitalized patients. 100 mg of pilocarpine is considered potent ially fatal. Overdosage should be treated withatropine titrat ion (0.5 mg to 1.0 mg given subcutaneously or intravenously) and supportive measures to maintain respiration and circulation. Epinephr ine (0.3 mg to 1.0 mg, subcutaneously or intramuscul arly) may also be of value in the presence of severe card iovascular depression or bronchoconstriction. It is not known if pilocarpine isdialyzable.
DOSAGE ANDADMINISTRATION:
Head & Neck Cancer Patients:
The recommendedinitial dose of SALAGEN' Tablets is one tabl et (5 mg) taken three times a day . Dosage should be titrated according to therapeutic response and tolerance. The usual dosage range is up to 3-6 tabletsor 15-30 mgper day . (Not to exceed 2 tablets perdose) Although early improvement may be realized, at least 12 weeks of uninterrupted therapy with SALAGEN' Tablets may be necessary to assess whether a beneficialresponse will be achieved. The incidence ofthemost common adverse eventsincreases withdose. The lowest dose that is tolerated and effectiveshould be used formaintenance.
SjOgren'sSyndrome Patients:
The recommended dose of SALAGEN' Tablets is one tablet (5 mg) taken fourtimes a day. Efficacywas established by6 weeks of use. Pilocarpine should be administered with caution to patients with known or suspected choleli thiasis or biliary tract disease. Contract ions of the gallbladder or bi liary smooth muscle could precipitate complications incl uding cholecystitis,cholangitis, andbiliary obstruction.
Pilocarpine may increase ureteral smooth muscle tone and could theoret ically precipitate renal colic (or "ureteral renux"), part icularly in patients withnephrolithiasis.
Cholinergic agonists may have dose-related central nervous system effects. This should be considered when treatingpat ients withunderlying cognitiveorpsychiatricdisturbances.
Renal tnsufficiency: The pharmacokinetics of orally admi nistered pilocarpine in pat ients with renal and hepatic disease is not known. Drug Interactions: Pilocarpine should be administered withcaution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. Drugs with parasympathomimetic effects administered concurrentlywith pilocarpine wou ld beexpected to resul t in additive pharmacologic effects. Pi locar pine might antagonize the anticholinergic effects of drugs used concomitantly. These effects should be considered when anticholinergic properties may be contributing to thetherapeutic effect of concom itan t medication (e.g., atropine, inhaled iprat ropium). 
Discussion
Skin testin g invo lves the intr odu ction of specific antigens onto or into the skin through a skin prick or an intrade rmal inoc ulat ion. Scratch testin g is no longer a reco mmended diagnostic procedure becau se it has been found to be insensitive and not reproducibl e, particul arly in co mpa rison with prick testing':' Th e skin prick is the test of choice of most ge neral allergists even though it has so me significant shor tco mings. Fir st, there is no meth od of standardizing and qu antifyin g the ski n res po nse. Second , the skin prick test does not dete rm ine the precise level of sensi tivity for specific antige ns . Fin ally, it misses low-sensiti vit y respon ses because it ca nnot detect allergic disease at sensitivi ties less than the co nce ntratio n of the antigen placed . As a result , immunotherapy based on skin prick testing mu st be started at doses sufficiently diluted to minimize the possibility of a sys temic reaction. Months to years might be needed before therapeutic level s are reached . Also, becau se antigen sensitivities vary, obtaining a ther apy-limiting respo nse from one antige n might be possibl e in so me patient s, while others receive far-from-optimal dosages. Seri al dilution quantitati ve intrad erm al testin g, also referred to as skin endpo int titration (SET), is a modi fied intraderm al test that uses specific ant igen dilut ion s to establi sh the min imum amount of antige n req uire d to produ ce a positive skin test, also referred to as the endpoint. SET differs fro m other skin tests in that it is designed to be prima rily a qu antitative rather than qu alitativ e test of allergen sensitivity. It identifies the endpo int for each ant igen by using 1:5 dilut ions of the allergen that is being tested . Th e endpoint identi fies not only which antige ns the patient is allergic to, it also indicates the patient ' s level of sensitivity to them and thu s provides a safe point from which the physician ca n initi ate imm unother apy. Th e endpoint does not correlate with sym ptom atology, and it does not predict the mainten ance dose of ther apy.
Once the different antige ns have been eva luated for reacti vity in this mann er, a treatment via l can be mixed that will include each clinically pertin ent antige n at its individual endpoint co nce ntratio n. There are se veral advantages to the SET method . First, it has the ab ility to deliv er antige n at a concentration that is safe and ye t close to the maximum toler ated level at the onset of treatm ent. As a result, it shortens the length of time needed to achieve sy mpto m relief, and it provides a means of advancing each antigen according to its particular level of sensitivity. Therefore, the physician can avo id the chance that a parti cul arl y high-sensiti vity anti gen will ca use a local or systemic reaction during dose escalation. Such a react ion would lim it the progression of the entire series and del ay the attai nme nt of ther apeuti c levels of other impor tant but less-sensiti ve anti gen s.
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Th e imp ort ance of quantifying skin reactivity during the eva luatio n and immuno thera pe utic treatment of allergic rhini tis ca nnot be ove remphas ized. Onl y those ski n tests that can quantify the patient ' s sensitivity to eac h antigen can provide the info rmatio n necessary to formulate an optimal treatment program.'
Our review of these 1,000 patient s who had undergone immunoth erapy based on SET tes ting indicates that SET is a safe technique, and its ability to quanti fy allergic sensitivity ca n maximize the potentia l that immunother apy will be successful.
